AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
Prestige Stones Launches as the World's Most Trusted Marketplace for...
Entergy Grid Renewal Projects Full Steam Ahead During National...
Women and Heart Disease: Those Most at Risk Are Most in Need of the...
Dr...
Severe Psoriasis Market Expected to Show Robust Growth Through 2032,...
African Nurses from Ghana and Kenya Selected as Finalists for Aster...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma

Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Tuesday that it has received European Commission approval for Calquence (acalabrutinib) in combination with bendamustine and rituximab as a first-line treatment for adult patients with mantle cell lymphoma...

If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search